Open-Label, Phase 2 Clinical Trial of Pre-Radiation and Post-Radiation Immunotherapy with N-803, ETBX-071, and M-CENK in Combination with Radiation for Participants with High-Risk Prostate Cancer
Latest Information Update: 10 Feb 2025
Price :
$35 *
At a glance
- Drugs ETBX- 071 (Primary) ; Memory cytokine enriched natural killer cell therapy-ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors ImmunityBio
- 17 Jan 2025 New trial record